[HTML][HTML] Prognostic and predictive response factors in colorectal cancer patients: between hope and reality
C De Divitiis, G Nasti, M Montano… - World Journal of …, 2014 - ncbi.nlm.nih.gov
Colorectal cancer (CRC) represents one of the most commonly diagnosed cancers
worldwide. It is the second leading cause of cancer death in Western Countries. In the last …
worldwide. It is the second leading cause of cancer death in Western Countries. In the last …
Electrolyte disorders associated with the use of anticancer drugs
G Liamis, TD Filippatos, MS Elisaf - European journal of pharmacology, 2016 - Elsevier
The use of anticancer drugs is beneficial for patients with malignancies but is frequently
associated with the occurrence of electrolyte disorders, which can be hazardous and in …
associated with the occurrence of electrolyte disorders, which can be hazardous and in …
Epidermal growth factor receptor: pathway, therapies, and pipeline
JR Goffin, K Zbuk - Clinical therapeutics, 2013 - Elsevier
Background The epidermal growth factor receptor (EGFR) pathway is important in tumor
growth, survival, and metastasis and is now the target of several therapeutic agents …
growth, survival, and metastasis and is now the target of several therapeutic agents …
[HTML][HTML] Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of …
Purpose The primary analysis of the ASPECCT study demonstrated that panitumumab was
non-inferior to cetuximab for overall survival (OS) in patients with chemotherapy-refractory …
non-inferior to cetuximab for overall survival (OS) in patients with chemotherapy-refractory …
Tumor calcification as a prognostic factor in cetuximab plus chemotherapy-treated patients with metastatic colorectal cancer
Y Zhou, J Zhang, D Pu, F Bi, Y Chen, J Liu, Q Li… - Anti-Cancer …, 2019 - journals.lww.com
This study aimed to explore the correlation between survival and tumor calcification in
patients with metastatic colorectal cancer who received cetuximab combined with …
patients with metastatic colorectal cancer who received cetuximab combined with …
Magnesium absorption in intestinal cells: evidence of cross-talk between EGF and TRPM6 and novel implications for cetuximab therapy
Hypomagnesemia is very commonly observed in cancer patients, most frequently in
association with therapy with cetuximab (CTX), a monoclonal antibody targeting the …
association with therapy with cetuximab (CTX), a monoclonal antibody targeting the …
Rates of hypomagnesemia and hypermagnesemia in medical settings.
A Catalano, F Bellone, D Chilà, S Loddo… - Magnesium …, 2021 - search.ebscohost.com
Magnesium (Mg) is critically involved in the pathophysiology of multiple human diseases;
nevertheless, Mg disorders are often poorly considered in the clinical practice. To update the …
nevertheless, Mg disorders are often poorly considered in the clinical practice. To update the …
Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: A systematic review and meta-analysis
MC Hsieh, CF Wu, CW Chen, CS Shi, WS Huang… - Scientific reports, 2018 - nature.com
Hypomagnesemia is a recognized side-effect of cetuximab-or panitumumab-based
chemotherapy for metastatic colorectal cancer (mCRC). The clinical relevance of …
chemotherapy for metastatic colorectal cancer (mCRC). The clinical relevance of …
Adverse kidney effects of epidermal growth factor receptor inhibitors
H Izzedine, MA Perazella - Nephrology Dialysis Transplantation, 2017 - academic.oup.com
The epidermal growth factor receptor (EGFR) is implicated in various malignancies. The past
decade has seen the development and widespread use of EGFR inhibitors for the …
decade has seen the development and widespread use of EGFR inhibitors for the …